The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

Waterdrop Inc. has been included in Harvard Business school’s (HBS) Case Collection. Inducted as a business innovation case, ...

Studies presented at the Society of Neurointerventional Surgery’s show links between GLP-1s and the prevention of strokes and ...

Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.

Dr. Ben Zeskind, CEO of Immuneering, discusses the new approach his company is taking to oncology.